@article{0332a46e7f4e4a729262da6b2c4860bc,
title = "Joint Asian Pacific Association of Gastroenterology (APAGE)-Asian Pacific Society of Digestive Endoscopy (APSDE) clinical practice guidelines on the use of non-invasive biomarkers for diagnosis of colorectal neoplasia",
abstract = "Screening for colorectal cancer (CRC) is effective in reducing CRC related mortality. Current screening methods include endoscopy based and biomarker based approaches. This guideline is a joint official statement of the Asian Pacific Association of Gastroenterology (APAGE) and the Asian Pacific Society of Digestive Endoscopy (APSDE), developed in response to the increasing use of, and accumulating supportive evidence for the role of, non-invasive biomarkers for the diagnosis of CRC and its precursor lesions. A systematic review of 678 publications and a two stage Delphi consensus process involving 16 clinicians in various disciplines was undertaken to develop 32 evidence based and expert opinion based recommendations for the use of faecal immunochemical tests, faecal based tumour biomarkers or microbial biomarkers, and blood based tumour biomarkers for the detection of CRC and adenoma. Comprehensive up-to-date guidance is provided on indications, patient selection and strengths and limitations of each screening tool. Future research to inform clinical applications are discussed alongside objective measurement of research priorities. This joint APAGE-APSDE practice guideline is intended to provide an up-to-date guide to assist clinicians worldwide in utilising non-invasive biomarkers for CRC screening; it has particular salience for clinicians in the Asia-Pacific region.",
keywords = "clinical decision making, colorectal cancer, screening, tumour markers",
author = "Chan, {Francis K.L.} and Wong, {Martin C.S.} and Chan, {Andrew T.} and East, {James E.} and Chiu, {Han Mo} and Makharia, {Govind K.} and David Weller and Ooi, {Choon Jin} and Julajak Limsrivilai and Yutaka Saito and Hang, {Dao V.} and Emery, {Jon D.} and Dadang Makmun and Kaichun Wu and Ali, {Raja Affendi Raja} and Ng, {Siew C.}",
note = "Funding Information: FKLC is Board Member of CUHK Medical Centre. He is a co-founder, non-executive Board Chairman and shareholder of GenieBiome Ltd. He receives patent royalties through his affiliated institutions. He has received fees as an advisor and honoraria as a speaker for Eisai Co. Ltd., AstraZeneca, Pfizer Inc., Takeda Pharmaceutical Co., and Takeda (China) Holdings Co. Ltd. MCSW is the honorary medical advisor of GenieBiome. He is an advisory committee member of Pfizer, external expert of GlaxoSmithKline, a member of the advisory board of AstraZeneca and has been paid consultancy fees for providing advice on research. ATC is a member of the AGA Governing Board and has received grant funding from Freenome for a colorectal cancer screening study. HM-C is the principal investigator, Taiwan CRC Screening Program, Asian Chair of WEO CRC screening committee and secretary general of the Gastroenterological Society of Taiwan (GEST), received research funding from Volition Rx, Eiken Chemical and Aether AI, and lecture honorarium from Olympus, Fuji and Eiken Chemical. JEE has served on clinical advisory boards for Paion, has served on the clinical advisory board and has share options in Satisfai Health and reports speaker fees from Falk, Jannsen and Medtronic. He was also part of the British Society of Gastroenterology guideline working group for 'Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC)'. He is funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health. KW has served as an advisory board member for BioChain (Beijing), Ferring, Janssen, Takeda and Abbvie, and a speaker for BioChain (Beijing), Ferring, Janssen, Abbvie, Everest and Takeda. He is named inventor of patent applications held by the FMMU and BioChain (Beijing) that cover the diagnostic use of ctDNA related to gastrointestinal cancers. SCN has served as an advisory board member for Pfizer, Ferring, Janssen, and Abbvie and received honoraria as a speaker for Ferring, Tillotts, Menarini, Janssen, Abbvie, and Takeda. SCN has received research grants through her affiliated institutions from Olympus, Ferring, and Abbvie. SCN is a scientific co-founder and shareholder of GenieBiome Ltd. SCN receives patent royalties through her affiliated institutions. Publisher Copyright: {\textcopyright} 2023 BMJ Publishing Group. All rights reserved.",
year = "2023",
month = jul,
day = "1",
doi = "10.1136/gutjnl-2023-329429",
language = "English",
volume = "72",
pages = "1240--1254",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "7",
}
